Novelix Pharma.

{
  "main_header": {
    "sid": 200695,
    "name": "Novelix Pharma.",
    "stock_name": "Novelix Pharma.",
    "full_name": "Novelix Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/novelix-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "52.05",
    "chg": -1.15,
    "chgp": "-2.16%",
    "dir": -1,
    "prev_price": "53.20",
    "mcapval": "113.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 536565,
    "symbol": "",
    "ind_name": "Retailing",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE314I01036",
    "curr_date": "Apr 09",
    "curr_time": "",
    "bse_nse_vol": "684 ",
    "exc_status": "Active",
    "traded_date": "Apr 09, 2026",
    "traded_date_str": "2026 04 09",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/novelix-pharma-200695-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Novelix Pharmaceuticals Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/novelix-pharmaceuticals-ltd-is-rated-hold-3935332",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/NovelixPharmace_mojoScore_3935332.png",
        "date": "2026-04-07 10:10:02",
        "description": "Novelix Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Novelix Pharmaceuticals Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/novelix-pharmaceuticals-ltd-is-rated-hold-3917977",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/NovelixPharmace_mojoScore_3917977.png",
        "date": "2026-03-26 10:10:02",
        "description": "Novelix Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 March 2026, providing investors with an up-to-date view of its performance and outlook."
      },
      {
        "title": "Novelix Pharmaceuticals Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/novelix-pharmaceuticals-ltd-is-rated-hold-3892239",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/NovelixPharmace_mojoScore_3892239.png",
        "date": "2026-03-15 10:10:02",
        "description": "Novelix Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 15 March 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Novelix Pharmaceuticals Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/novelix-pharmaceuticals-ltd-is-rated-hold-3869064",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/NovelixPharmace_mojoScore_3869064.png",
        "date": "2026-03-04 10:10:02",
        "description": "Novelix Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 March 2026, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "Novelix Pharmaceuticals Ltd Falls 2.26%: Key Valuation and Quality Shifts Shape Weekly Trend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novelix-pharmaceuticals-ltd-falls-226-key-valuation-and-quality-shifts-shape-weekly-trend-3863215",
        "imagepath": "",
        "date": "2026-03-01 13:00:05",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>16 Feb:</strong> Quality grade upgraded to average; valuation shifts from very expensive to expensive</p>\n                    <p><strong>17 Feb:</strong> Stock declines 2.56% despite Sensex gains</p>\n                    <p><strong>18 Feb:</strong> Strong rebound with 4.59% gain on heavy volume</p>\n                    <p><strong>19 Feb:</strong> Market correction impacts stock, down 1.95%</p>\n                    <p><strong>20 Feb:</strong> Week closes lower at Rs.61.04, down 3.05% on the day</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.62.45</div></div..."
      },
      {
        "title": "Novelix Pharmaceuticals Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/novelix-pharmaceuticals-ltd-is-rated-hold-3849418",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/NovelixPharmace_mojoScore_3849418.png",
        "date": "2026-02-21 10:10:05",
        "description": "Novelix Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Novelix Pharmaceuticals Ltd Valuation Shift Signals Price Attractiveness Change",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novelix-pharmaceuticals-ltd-valuation-shift-signals-price-attractiveness-change-3841337",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/NovelixPharmace_valuationdot_3841337.png",
        "date": "2026-02-16 08:00:32",
        "description": "Novelix Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a very expensive to an expensive rating, reflecting evolving investor perceptions amid mixed financial metrics and sector comparisons. This article analyses the recent changes in key valuation ratios, their implications for price attractiveness, and how Novelix stacks up against its peers in the retailing sector."
      },
      {
        "title": "Novelix Pharmaceuticals Ltd Quality Grade Upgrade Signals Mixed Business Fundamentals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novelix-pharmaceuticals-ltd-quality-grade-upgrade-signals-mixed-business-fundamentals-3841310",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/NovelixPharmace_qualitydot_3841310.png",
        "date": "2026-02-16 08:00:18",
        "description": "Novelix Pharmaceuticals Ltd has seen its quality grade upgraded from below average to average, reflecting a nuanced shift in its business fundamentals. While the company demonstrates impressive sales growth and a clean debt profile, key profitability metrics such as ROCE and ROE remain subdued, indicating areas of concern for investors seeking consistent returns."
      },
      {
        "title": "Novelix Pharmaceuticals Declines 2.04% Despite Strong Quarterly Growth: 3 Key Factors Behind the Week’s Moves",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novelix-pharmaceuticals-declines-204-despite-strong-quarterly-growth-3-key-factors-behind-the-weeks-moves-3841095",
        "imagepath": "",
        "date": "2026-02-15 14:00:05",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>Feb 9:</strong> Stock opens at Rs.62.56, declines 1.87% amid broad market gains</p>\n                    <p><strong>Feb 10:</strong> Modest recovery with 0.67% gain to Rs.62.98</p>\n                    <p><strong>Feb 12:</strong> Sharp fall of 2.06% to Rs.61.29 on weak market sentiment</p>\n                    <p><strong>Feb 13:</strong> Strong quarterly results announced; stock rebounds 1.89% to Rs.62.45</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.63.75</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div ..."
      }
    ],
    "total": 115,
    "sid": "200695",
    "stock_news_url": "https://www.marketsmojo.com/news/novelix-pharmaceuticals-200695"
  },
  "announcements": [
    {
      "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
      "datetime": "02-Apr-2026",
      "details": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Srinidhi Fine Chemicals LLP",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Resignation of Director",
      "datetime": "31-Mar-2026",
      "details": "Submission of Intimation of Resignation of Director of the Company.",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "31-Mar-2026",
      "details": "Submission of intimation of closure of trading window.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Novelix Pharmaceuticals Ltd has declared <strong>3%</strong> dividend, ex-date: 16 Aug 12",
          "dt": "2012-08-16",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Novelix Pharmaceuticals Ltd has announced <strong>10:1</strong> stock split, ex-date: 04 Oct 10",
          "dt": "2010-10-04",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Novelix Pharmaceuticals Ltd is Rated Hold

2026-04-07 10:10:02

Novelix Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Novelix Pharmaceuticals Ltd is Rated Hold

2026-03-26 10:10:02

Novelix Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 March 2026, providing investors with an up-to-date view of its performance and outlook.

Read full news article

Novelix Pharmaceuticals Ltd is Rated Hold

2026-03-15 10:10:02

Novelix Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 15 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Novelix Pharmaceuticals Ltd is Rated Hold

2026-03-04 10:10:02

Novelix Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 March 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

Novelix Pharmaceuticals Ltd Falls 2.26%: Key Valuation and Quality Shifts Shape Weekly Trend

2026-03-01 13:00:05

Key Events This Week

16 Feb: Quality grade upgraded to average; valuation shifts from very expensive to expensive

17 Feb: Stock declines 2.56% despite Sensex gains

18 Feb: Strong rebound with 4.59% gain on heavy volume

19 Feb: Market correction impacts stock, down 1.95%

20 Feb: Week closes lower at Rs.61.04, down 3.05% on the day

Week Open

Rs.62.45

Read full news article

Novelix Pharmaceuticals Ltd is Rated Hold

2026-02-21 10:10:05

Novelix Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Novelix Pharmaceuticals Ltd Valuation Shift Signals Price Attractiveness Change

2026-02-16 08:00:32

Novelix Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a very expensive to an expensive rating, reflecting evolving investor perceptions amid mixed financial metrics and sector comparisons. This article analyses the recent changes in key valuation ratios, their implications for price attractiveness, and how Novelix stacks up against its peers in the retailing sector.

Read full news article

Novelix Pharmaceuticals Ltd Quality Grade Upgrade Signals Mixed Business Fundamentals

2026-02-16 08:00:18

Novelix Pharmaceuticals Ltd has seen its quality grade upgraded from below average to average, reflecting a nuanced shift in its business fundamentals. While the company demonstrates impressive sales growth and a clean debt profile, key profitability metrics such as ROCE and ROE remain subdued, indicating areas of concern for investors seeking consistent returns.

Read full news article

Novelix Pharmaceuticals Declines 2.04% Despite Strong Quarterly Growth: 3 Key Factors Behind the Week’s Moves

2026-02-15 14:00:05

Key Events This Week

Feb 9: Stock opens at Rs.62.56, declines 1.87% amid broad market gains

Feb 10: Modest recovery with 0.67% gain to Rs.62.98

Feb 12: Sharp fall of 2.06% to Rs.61.29 on weak market sentiment

Feb 13: Strong quarterly results announced; stock rebounds 1.89% to Rs.62.45

Week Open

Rs.63.75

Week Close

Read full news article

View All News